Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP and PPP Eye Drops for Ocular Graft-Versus-Host Disease
NCT02561520Phase 1Withdrawn
- Start
- Dec 2016
- Primary completion
- Sep 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous platelet-rich plasma eye drops in ocular graft-versus-host disease (oGVHD). Primary endpoint: Number of Participants With Treatment-Related Adverse Events at 8 weeks. Planned start Dec 2016; status: withdrawn.
02
Drugs
autologous platelet-rich plasma eye drops
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on NCT02561520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561520.